Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2026-02-04 00:00:00 ET · period of report 2026-02-02 · accession 0001591467-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-02-04 | 2026-02-02 | AKBA | Butler John P. | CEO, Pres, Dir | A - Grant | $1.41 | +175.2K | 3.38M | +5% | +$247.1K |
| MT | 2026-02-04 | 2026-02-02 | AKBA | Butler John P. | CEO, Pres, Dir | S - Sale | $1.39 | -341.3K | 3.42M | -9% | -$474.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-02 | A | A | 175,250 | $1.41 | 3,381,483 | D | — | — | (F5) As reported in February 2025, the Reporting Person was granted performance-based restricted stock units ("PSUs") pursuant to the Issuer's 2023 Stock Incentive Plan, as amended. Each PSU right represents a contingent right to receive one share of the Issuer's common stock. One-half of the total number of shares of common stock underlying the PSUs vests on the later of (i) the first anniversary of the grant date and (ii) the date that the Compensation Committee certifies that the average closing price of the Issuer's common stock equals or exceeds $3.50 over a 30-day trading period (the "Stock Price Hurdle 1 Performance Condition"), subject to the reporting persons continuous employment through the applicable vesting date. In July2025, the Compensation Committee certified that the Stock Price Hurdle 1 Performance Condition was met during the performance period and therefore one-half of the PSUs vested on January 31, 2026. |
| 2 | Common | Common Stock | 2026-02-02 | S | D | 83,689 | $1.39 | 3,297,794 | D | — | — | (F6) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's performance stock units granted on January 31, 2025. (F2) This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025. |
| 3 | Common | Common Stock | 2026-02-02 | S | D | 114,891 | $1.39 | 3,206,233 | D | — | — | (F4) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025. (F2) This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025. |
| 4 | Common | Common Stock | 2026-02-02 | S | D | 96,065 | $1.39 | 3,321,124 | D | — | — | (F2) This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025. (F3) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024. |
| 5 | Common | Common Stock | 2026-02-02 | S | D | 46,660 | $1.39 | 3,417,189 | D | — | — | (F2) This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025. (F1) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023. |